The pharmaceutical industry faces continued pressure to reduce cost and improve speed of new medicines development, as well as adapt to the ever-changing global regulatory landscape. The cost of drug development continues to rise and is doing so at a rate that is outpacing the expected growth in net revenue for pharmaceutical companies. This is an unsustainable scenario; one that will require industry leaders to re-examine the nature of the enterprise required for future success in this changing marketplace.
Large, multi-national pharmaceutical firms use extensive internal infrastructure to support the development of therapies. While use of third-party providers has allowed flexibility in approaches to staffing capabilities like clinical monitoring or safety reporting, many have continued to rely upon ownership of internal processes and systems.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings